1. Home
  2. CORT vs SF Comparison

CORT vs SF Comparison

Compare CORT & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$89.23

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Logo Stifel Financial Corporation

SF

Stifel Financial Corporation

HOLD

Current Price

$72.77

Market Cap

11.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CORT
SF
Founded
1998
1890
Country
United States
United States
Employees
730
9000
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
11.4B
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
CORT
SF
Price
$89.23
$72.77
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$96.50
$90.33
AVG Volume (30 Days)
957.9K
1.4M
Earning Date
04-30-2026
04-22-2026
Dividend Yield
N/A
1.76%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$761,407,000.00
N/A
Revenue This Year
$26.08
$14.58
Revenue Next Year
$26.98
$8.03
P/E Ratio
N/A
$20.53
Revenue Growth
12.79
N/A
52 Week Low
$28.66
$67.81
52 Week High
$91.00
$134.74

Technical Indicators

Market Signals
Indicator
CORT
SF
Relative Strength Index (RSI) 80.68 53.70
Support Level $76.41 $68.63
Resistance Level N/A $74.68
Average True Range (ATR) 3.76 1.81
MACD -0.09 0.09
Stochastic Oscillator 94.20 71.72

Price Performance

Historical Comparison
CORT
SF

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

About SF Stifel Financial Corporation

Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.

Share on Social Networks: